This is a multicenter, prospective, randomized, controlled trial. A total of 165 patients with idiopathic trigeminal neuralgia will be enrolled and randomly divided into three groups at a 1:1:1 ratio. The aim is to compare the efficacy and safety of conventional carbamazepine monotherapy, carbamazepine combined with oral antiviral therapy, and carbamazepine combined with anti-inflammatory therapy in pain relief, quality of life improvement and adverse event profiles.
Diagnosed with idiopathic trigeminal neuralgia according to standard clinical criteria.
No secondary etiology confirmed by cranial imaging.
No severe systemic disease or immune system disease.
Voluntary participation and signed informed consent.
Secondary trigeminal neuralgia of any cause.
Active herpes zoster infection recently.
Severe hepatic or renal insufficiency or contraindications to study drugs.
Unable to complete questionnaire evaluation independently.
Beijing Tiantan Hospital
Lead sponsor
Beijing Sanbo Brain Hospital
Collaborator